Alzheimer's disease (AD) and type 2 diabetes appear to share similar pathogenic mechanisms. dsRNA-dependent protein kinase (PKR) underlies peripheral insulin resistance in metabolic disorders. PKR phosphorylates eukaryotic translation initiation factor 2a (eIF2a-P), and AD brains exhibit elevated phospho-PKR and eIF2a-P levels. Whether and how PKR and eIF2a-P participate in defective brain insulin signaling and cognitive impairment in AD are unknown. We report that b-amyloid oligomers, AD-associated toxins, activate PKR in a tumor necrosis factor a (TNF-a)-dependent manner, resulting in eIF2a-P, neuronal insulin receptor substrate (IRS-1) inhibition, synapse loss, and memory impairment. Brain phospho-PKR and eIF2a-P were elevated in AD animal models, including monkeys given intracerebroventricular oligomer infusions. Oligomers failed to trigger eIF2a-P and cognitive impairment in PKR À/À and TNFR1 À/À mice. Bolstering insulin signaling rescued phospho-PKR and eIF2a-P. Results reveal pathogenic mechanisms shared by AD and diabetes and establish that proinflammatory signaling mediates oligomer-induced IRS-1 inhibition and PKR-dependent synapse and memory loss.
INTRODUCTION
Recent evidence suggests that Alzheimer's disease (AD) is a novel, brain-specific form of diabetes (de la Monte and Wands, 2008; De Felice, 2013) . AD brains exhibit defective insulin signaling with altered levels and cellular distribution of insulin receptors (Moloney et al., 2010) . Insulin signaling is central to neuronal survival, regulation of synapse number, and dendritic plasticity (van der Heide et al., 2005; Chiu et al., 2008; McNay and Recknagel, 2011) , raising the possibility that deficient insulin signaling may be linked to neuronal dysfunction in AD.
b-amyloid oligomers (AbOs), toxins that accumulate in AD brains and instigate synapse damage (Ferreira and Klein, 2011) , remove insulin receptors from the neuronal surface De Felice et al., 2009 ) and activate c-Jun N-terminal kinase (JNK) to trigger insulin receptor substrate (IRS-1) inhibition (Bomfim et al., 2012) . These findings provided initial clues on how impaired neuronal insulin signaling develops in AD (De Felice, 2013) . Landmark studies from the diabetes field have established that activation of proinflammatory tumor necrosis factor alpha and JNK signaling (TNF-a/JNK signaling) is a key mechanism leading to peripheral insulin resistance (Hotamisligil et al., 1994 (Hotamisligil et al., , 1996 Gregor and Hotamisligil, 2011) . Therefore, it is likely that a molecular parallel exists between defective brain insulin signaling in AD and peripheral insulin resistance in diabetes (Bomfim et al., 2012; De Felice, 2013) .
The double-stranded RNA-dependent protein kinase (PKR) is a critical player in the integration of an inflammatory response that leads to peripheral insulin resistance in metabolic disorders, including diabetes (Ozcan et al., 2004; Hotamisligil, 2010; Nakamura et al., 2010) . Elevated levels of phosphorylated PKR and of its key target, eukaryotic translation initiation factor 2a (eIF2a), have been reported in AD brains and in animal models of AD (Hoozemans et al., 2009; Yoon et al., 2012) . eIF2a phosphorylation is critical for memory regulation (Costa-Mattioli et al., 2007) and has been recently shown to mediate prion-related neurodegeneration in the hippocampus (Moreno et al., 2012) , a memory center that is affected early in AD.
Given the pathophysiological roles of TNF-a and PKR in peripheral insulin resistance (Nakamura et al., 2010; Gregor and Hotamisligil, 2011) , we investigated here whether similar proinflammatory mechanisms might underlie neuronal dysfunction in AD. We hypothesized that the TNF-a pathway might cause phosphorylation of PKR and eIF2a-P, IRS-1 inhibition, and impact synapses and memory in AD. We show that phospho-PKR and eIF2a-P are elevated in the brains of a transgenic mouse model of AD, of mice and cynomolgus monkeys given intracerebroventricular (i.c.v.) infusions of AbOs, and in cultured hippocampal neurons exposed to oligomers. AbOs failed to trigger eIF2a-P and cognitive impairment in both PKR À/À and TNFR1 À/À mice, as well as in mice treated with infliximab, a TNF-a neutralizing antibody. Salubrinal and thapsigargin, agents that increase eIF2a-P levels and endoplasmic reticulum (ER) stress, respectively, induced memory impairment in mice. Insulin treatment prevented oligomer-induced phosphorylation of PKR and eIF2a-P in hippocampal cultures. Glucagon-like peptide 1 (GLP-1) receptor agonists blocked eIF2a-P in hippocampal cultures and in the brains of transgenic mice and oligomer-injected monkeys. Collectively, results provide the grounds for targeting TNF-a/PKR/eIF2a-P signaling as a potential disease-modifying therapy for AD.
RESULTS

Ab Oligomers Instigate Neuronal eIF2a-P and Other ER Stress Markers In Vitro and In Vivo
We first explored whether AbOs abnormally activate the unfolded protein response (UPR), which has been described to intersect with inflammatory and stress signaling pathways that lead to peripheral insulin resistance in chronic metabolic diseases (Ozcan et al., 2004 (Ozcan et al., , 2006 Hotamisligil, 2010) . To this end, we searched for ER stress markers in cell cultures and in different animal models of AD. Using mature cultured hippocampal neurons, we found increased IRE1a-pSer724 in dendrites and cell bodies after exposure of neurons to AbOs for 3 hr (Figures 1A and 1B and S1A available online) . Consistent with increased endonuclease activity of IRE1a upon phosphorylation, levels of spliced X box binding protein 1 (XBP1), a downstream effector of IRE1a recently proposed as a connection between UPR and insulin signaling (Park et al., 2010; Winnay et al., 2010) , were increased in oligomer-exposed neurons (Figure S1B) . Further, AbOs increased dendritic and cell body levels of eIF2a-pSer51 (eIF2a-P) in hippocampal neurons ( Figures 1C,  1D , and S1C). We also detected increased neuronal levels of 78 kDa glucose-regulated protein (GRP78) (also known as binding immunoglobulin protein, Bip), an ER chaperone that is part of the stress response program and is upregulated in AD brains (Hoozemans et al., 2005) , in oligomer-exposed neurons (Figure S1D ). Prolonged ER stress is known to trigger apoptosis mediated by C/EBP homologous protein (CHOP; also known as growth arrest-and DNA damage-inducible gene 153, GADD153) (Lai et al., 2007) . In line with the results described above, CHOP mRNA levels were increased in neurons exposed to AbOs for 24 hr ( Figure S1E ).
Next, we looked for eIF2a-P in the brains of APPSwe,PS1DE9 (APP/PS1) mice. These mice harbor transgenes for human amyloid precursor protein (APP) bearing the Swedish mutation and a deletion mutant form of presenilin 1 (PS1) and present increased Ab production and cognitive deficits (Jankowsky et al., 2001) . APP/PS1 mice displayed increased hippocampal levels of eIF2a-P compared to wild-type animals ( Figure 1E ). (Gkogkas et al., 2010) . PERK and PKR are the main eIF2a kinases in response to ER stress and inflammation, respectively (Raven and Koromilas, 2008) . We therefore examined the roles of both kinases in oligomer-induced eIF2a-P in neurons. In hippocampal neuronal cultures, the distribution of activated PERK (PERK-pThr981) was mainly restricted to cell bodies, and its levels were not altered by exposure to AbOs for 3 hr ( Figures S2A and S2B ). In contrast, PKR was activated by exposure to AbOs in neuronal cultures (Figures 1F and 1G) . AbOs are known to selectively target a subset of neurons in hippocampal cultures (Lacor et al., 2007) . Importantly, elevated phospho-PKR levels were found independent of whether or not neurons exhibited oligomers bound to their dendrites ( Figure 1H ). This indicates that PKR phosphorylation is not triggered by direct binding of oligomers to individual neurons, but rather is instigated by soluble factors released to the medium upon exposure of cultures to AbOs.
AbO
To establish the in vivo relevance of these findings, we analyzed levels of active PKR and PERK in the brains of APP/ PS1 transgenic mice. Increased phosphorylation of PKR, but not of PERK, was detected in hippocampi of APP/PS1 mice compared to wild-type controls (Figures 1I and S2C) . Consistent with the role of PKR in AbO-dependent eIF2a-P, pharmacological inhibition of PKR completely blocked oligomer-induced eIF2a-P as well as in cultured hippocampal neurons. We further extended our investigation to the brains of monkeys that received i.c.v. infusions of AbOs. In monkeys, AbOs promoted eIF2a-P ( Figures 1L, 1M , S1F, and S1G) and PKR activation in the hippocampus and entorhinal cortex ( Figures 1N, 1O , S1H, and S1I).
TNF-a Receptor Activation Lies Upstream of PKR Dysregulation
In metabolic disorders, ER stress has been linked to insulin resistance and proinflammatory TNF-a signaling (Ozcan et al., 2006; Steinberg et al., 2006) . To determine whether TNF-a activation was involved in AbO-induced phospho-PKR and eIF2a-P in hippocampal neurons, we first treated cultures with infliximab, a Figure 1 . b-Amyloid Oligomers Trigger Neuronal IRE1a-pSer724, eIF2a-P, and Phospho-PKR In Vitro and In Vivo (A and B) Shown is IRE1a-pSer724 immunolabeling (A) and levels (B) in cultured hippocampal neurons exposed to vehicle or 500 nM AbOs for 3 hr (scale bars = 10 mm). Boxes under each panel show optical zoom images of selected dendrite segments (white dashed rectangles). (C and D) Shown is eIF2a-P immunolabeling (C) and levels (D), determined from 4-6 experiments using independent cultures (30 images analyzed per experimental condition per experiment). (E) Immunoblot analysis of eIF2a-P in hippocampal homogenates from 13-to 16-month-old WT (n = 5) or APP/PS1 (n = 7) mice. (F) Immunolabeling for PKR-pThr451 in cultured hippocampal neurons exposed to vehicle or 500 nM AbOs for 3 hr (scale bar = 10 mm). (G) PKR-pThr451 immunofluorescence levels, determined from four experiments using independent cultures (30 images analyzed per experimental condition per experiment). (H) Immunolabeling of DAPI (blue), AbOs (red), and phospho-PKR (green) in cultured hippocampal neurons. White arrow indicates a neuron with elevated phospho-PKR level in the absence of oligomer binding. (I) Immunoblot analysis of PKR-pThr451 (normalized by total PKR) in hippocampal homogenates of 13-to 16-month-old WT (n = 5) and APP/PS1 (n = 7) mice. *p < 0.05, **p < 0.01, Student's t test. (J) eIF2a-P immunolabeling in hippocampal neurons exposed to vehicle, 500 nM AbOs, or 1 mM PKR inhibitor + 500 nM AbOs for 3 hr (scale bar = 10 mm). (K) eIF2a-P and IRE1a-pSer724 immunofluorescence levels, determined from three experiments using independent cultures. *p < 0.05, ANOVA followed by Bonferroni post hoc test. (L and M) Shown is eIF2a-P immunolabeling (L) and integrated optical densities (M) in hippocampus (CA1 and CA3 regions) and entorhinal cortex of cynomolgus monkeys that received i.c.v. injections of AbOs (n = 4) (right panels) compared to sham-operated control monkeys (n = 3) (left panels) (scale bars = 200 mm). (N and O) Shown is phosphor-PKR labeling (N) and integrated optical densities (O) (see Experimental Procedures) in hippocampus (CA1 and CA3 regions) and entorhinal cortex of sham-operated (Sham) (n = 3) or AbO-injected monkeys (AbOs) (n = 4). *p < 0.05, ANOVA followed by Bonferroni post hoc test. Graphs show means ± SEM. See also Figure S1 .
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and Memory TNF-a neutralizing monoclonal antibody. Infliximab suppressed both PKR activation and eIF2a-P triggered by oligomers ( Figures  2A-2E ). SP600125, a specific JNK inhibitor, also blocked eIF2a-P in neuronal cultures ( Figures 2D and 2E ), in line with recent studies that have implicated the JNK pathway in AbO-induced IRS-1 inhibition (Ma et al., 2009; Bomfim et al., 2012; De Felice, 2013) . It is notable that infliximab did not block oligomer binding to neurons ( Figures 2F and 2G ), substantiating the notion that activation of TNF-a/PKR signaling is independent of direct binding of AbOs to individual neurons and is likely mediated by TNF-a secreted to the medium. Indeed, TNF-a levels were increased in the culture medium after exposure to oligomers ( Figure 2H ), consistent with our recent finding that TNF-a levels are increased in the brains of mice that received i.c.v infusions of oligomers .
Activation of the TNF-a/PKR/eIF2a-P Pathway Is Linked to Synapse Loss and Memory Impairment We next hypothesized that activation of proinflammatory TNF-a signaling might be connected to AbO-induced memory impairment. Supporting this hypothesis, infliximab prevented memory impairment triggered by AbOs in mice ( Figure 3A ). We next injected oligomers i.c.v. in TNFR1 À/À mice. Significantly, AbOs caused memory deficits in wild-type (WT) mice, but not in TNFR1 À/À mice ( Figures 3B, 3C , and S3). These results implicate TNF-a signaling in the mechanism underlying memory impairment induced by AbOs in mice. Interestingly, AbOs triggered phosphorylation of PKR and eIF2a in the hippocampus of WT mice, but not in TNFR1 À/À mice ( Figures 3D and 3E ), establishing that activation of TNF-a receptors lies upstream of PKR and eIF2a-P in vivo. Synapse loss has been proposed to be the best pathological correlate of the extent of dementia in AD (Terry et al., 1991) , and AD brains present reduced levels of synaptophysin and PSD-95, pre-and postsynaptic markers, respectively (Terry et al., 1991) . AbOs have been shown to reduce the levels of synaptophysin or PSD-95 in neuronal cultures, in the brains of mice receiving i.c.v. infusions of oligomers, and in ex vivo human cortical slices (Sebollela et al., 2012; Figueiredo et al., 2013) . Supporting the notion that synaptic deterioration underlies TNF-a-dependent memory impairment induced by AbOs, levels of synaptophysin and PSD-95 were decreased in hippocampi of WT, but not of TNFR1 À/À , mice i.c.v. injected with AbOs ( Figure 3F ). To determine the role of PKR in AbO-induced cognitive impairment, we investigated the effect of AbOs in PKR À/À mice. Importantly, we found that AbOs induced hippocampal eIF2a-P and cognitive deficits in WT mice, but not in PKR À/À mice ( Figures   3G-3I ). These results demonstrate that PKR, recently implicated in metabolic stress and impaired insulin signaling in diabetes (Nakamura et al., 2010) , is a key mediator of neuronal eIF2a-P and memory impairment induced by AbOs.
To further examine the impact of PKR activation on synapses, we exposed hippocampal cultures to AbOs in the absence or presence of a PKR inhibitor. After 24 hr, we evaluated synapse (C) eIF2a-P immunolabeling in cultured hippocampal neurons exposed for 3 hr to vehicle or 500 nM AbOs in the absence or presence of infliximab. (D) eIF2a-P immunofluorescence levels, determined from four experiments using independent cultures exposed to vehicle or 500 nM AbOs in the absence or presence of infliximab or JNK inhibitor (JNKi). **p < 0.01, ANOVA followed by Bonferroni post hoc test. (E) Immunoblot analysis for eIF2a-P in hippocampal neuronal cultures exposed for 3 hr to 500 nM AbOs in the absence or in the presence of infliximab or JNK inhibitor (n = 3 independent experiments; *p < 0.05, Student's t test). (F) Imunolabeling of AbOs (with anti-AbO, NU4) in neurons exposed to 500 nM AbOs in the absence or presence of infliximab. (G) Quantification of Ab oligomer binding in neurons exposed to AbOs in the absence or presence of infliximab. (H) Soluble TNF-a levels in conditioned media from cultured hippocampal neurons exposed to vehicle (veh) or 500 nM AbOs for 3 hr (n = 3 independent experiments; *p < 0.05, Student's t test). Graphs show means ± SEM. See also Figure S2 .
TNF-a, PKR, Insulin Signaling, and Memory density by determining immunoreactivities of synaptophysin and PSD-95 and their colocalization at synapses. Results showed that inhibition of PKR attenuated synapse loss induced by AbOs ( Figures 3J-3M ) and suggest that loss of synaptic proteins underlies the deleterious effects of PKR on memory.
Based on the findings described above, we hypothesized that elevated eIF2a-P in the brain might be linked to memory impairment triggered by AbOs. To explore the connection between eIF2a-P and memory, we performed i.p. injections of salubrinal (an inhibitor of GADD34, a phosphatase that preferentially dephosphorylates eIF2a) to increase eIF2a-P levels in the hippocampi of adult Swiss mice. Animals that received salubrinal presented memory impairment in the novel object recognition task ( Figure 4A ) and significantly lower hippocampal levels of PSD-95 and synaptophysin ( Figures 4B-4D ). We also found decreased levels of synaptophysin and PSD-95, as well as decreased synapse density, in salubrinal-exposed hippocampal cultures ( Figures 4E-4H ). Control experiments indicated that, as expected, salubrinal promoted eIF2a-P in hippocampal neurons in culture ( Figures S4A and S4B ) and in the brains of injected mice ( Figure S4C ). These results show that eIF2a-P is sufficient to cause memory impairment and synapse loss in mice.
Additional support to the notion that eIF2a-P and, more generally, ER stress cause memory impairment came from the observation that thapsigargin, a classical inducer of ER stress that triggers eIF2a-P in neurons ( Figures S5A and S5B ), caused brain eIF2a-P and memory impairment when injected i.c.v. in mice ( Figures S5C and S5D ). 4-phenylbutyrate (4-PBA), a chemical pmol AbOs (n = 7 for each experimental condition).
(G) Exploration times of WT or PKR À/À mice exposed to vehicle or 10 pmol AbOs in the novel object recognition task (n = 8-10 per experimental group). Asterisks denote a statistically significant difference (p < 0.05) from 50% (reference value).
(H) Freezing times of WT or PKR À/À mice injected with vehicle or 10 pmol AbOs in the contextual fear conditioning task. n = 9-10 animals per experimental group. *p < 0.05, ANOVA followed by Bonferroni post hoc test.
(I) Immunoblot analysis of eIF2a-P (normalized by total eIF2a) in hippocampal homogenates of 2-to 3-month-old WT or PKR À/À mice injected with vehicle or 10 pmol AbOs (n = 7 for each experimental condition).
(J) Synaptophysin (green) and PSD95 (red) immunolabeling of cultured hippocampal neurons exposed for 3 hr to vehicle or 500 nM AbOs in the absence or presence of PKR inhibitor. Synapses, evidenced by colocalized puncta, appear in yellow.
, and colocalized (M) puncta, determined from four experiments using independent cultures. *p < 0.05, ANOVA followed by Bonferroni post hoc test. Graphs show means ± SEM. See also Figure S3 .
Cell Metabolism TNF-a, PKR, Insulin Signaling, and Memory chaperone known to alleviate ER stress, prevented memory loss ( Figure S5D ). 4-PBA further blocked memory impairment caused by i.c.v. injection of AbOs in mice ( Figure S5E ), implicating ER stress in the impact of AbOs on memory.
TNF-a, but Not eIF2a-P, Causes Neuronal IRS-1 Inhibition We recently reported that TNF-a and PKR mediate IRS-1 inhibition in cultured hippocampal neurons (Bomfim et al., 2012) . Establishing that proinflammatory TNF-a mediates oligomerinduced IRS-1 inhibition in vivo, AbOs triggered IRS-1pSer636 in the hippocampus of WT mice, but not in TNFR1 À/À mice ( Figure 5A ). We also examined IRS-1pSer levels in the brains of PKR À/À mice. Possibly reflecting different patterns of activation of IRS-1 in mice of different genetic backgrounds (Xu et al., 2013) , we did not detect increased IRS-1pSer levels induced by AbOs in WT 129/SvEv mice. Interestingly, however, lower IRS-1pSer levels were found in PKR À/À mice than in WT mice, demonstrating that suppression of PKR per se attenuates IRS-1 inhibition ( Figure 5B ). Because ER stress and eIF2a-P are linked to insulin resistance in peripheral tissues (Ozcan et al., 2004; Birkenfeld et al., 2011) , we next aimed to determine whether they might be related to IRS-1 inhibition in neurons. We initially found that thapsgargin triggered dendritic IRS-1pSer636 in hippocampal neurons, and this was blocked by 4-PBA ( Figures 5C and 5D ). However, levels of IRS-1pSer were unaffected in hippocampal neuronal cultures exposed to salubrinal ( Figures 5E and 5F ) or in hippocampi of salubrinal-injected mice ( Figures 5G and 5H) . These results suggest that, while eIF2a-P alone is not sufficient to cause IRS1pSer in neurons, aberrant activation of TNF-a signaling and induction of ER stress play important roles in brain IRS-1 inhibition. In this regard, it is interesting to note that AbOs induced upregulation of XBP1s, GRP78, and CHOP ( Figures S1B, S1D , and S1E), implicated in mechanisms by which ER dysfunction is linked to inflammatory signaling and insulin resistance (Hotamisligil, 2010) . Based on our results, it is conceivable that different branches of the UPR respond to AbO-induced TNFR activation and lead to IRS-1 inhibition.
Stimulation of Insulin Signaling Prevents Phospho-PKR and eIF2a-P Lastly, we asked whether antidiabetic agents, recently shown to restore insulin signaling and exert neuroprotective actions in AD models (De Felice et al., 2009; McClean et al., 2011; Bomfim et al., 2012) , could alleviate phospho-PKR and eIF2a-P triggered by AbOs. Insulin treatment blocked the phosphorylation of PKR and eIF2a in hippocampal cultures exposed to AbOs ( Figures  6A-6D ). Exendin-4, a GLP-1 receptor agonist approved for treatment of diabetes (Ryan and Hardy, 2011) , blocked AbO-triggered eIF2a-P in hippocampal neurons ( Figures 6C and 6D) , and intraperitoneal treatment with exendin-4 rescued eIF2a-P levels in hippocampi of APP/PS1 mice ( Figure 6E ).
Liraglutide, a long-lasting GLP-1 receptor agonist, has also been shown to exhibit neuroprotective actions in animal models. Liraglutide treatment significantly reduced the levels of ER stress marker GRP78 in the brains of APP/PS1 mice ( Figure S6A ). This was accompanied by a significant increase in levels of synaptic marker drebrin ( Figure S6B ), suggesting increased synaptic density. We further asked whether liraglutide would affect hippocampal Ab oligomer burden in APP/PS1 mice. Interestingly, levels of 28 kDa and 108 kDa Ab oligomers, recently implicated in AD pathogenesis (Tomiyama et al., 2010; Bao et al., 2012) , were markedly reduced in liraglutide-treated animals ( Figures  S6C and S6D) .
The neuroprotective actions of exendin-4 and liraglutide translated into memory benefit, as indicated by improved performance in fear conditioning learning in APP/PS1 mice ( Figures  S6E and S6F ). These findings are in line with recent studies that demonstrated beneficial effects of GLP-1R activation on memory in AD mice (McClean et al., 2011; Bomfim et al., 2012) . Control measurements showed that neither exendin-4 nor liraglutide altered animal body weight during experiments ( Figures S6G and S6H) . Collectively, these data suggest that (E) Synaptophysin (green) and PSD95 (red) immunolabeling in cultured hippocampal neurons exposed for 3 hr to vehicle or 10 mM salubrinal. Synapses, evidenced by colocalized puncta, appear in yellow. (F-H) Quantification of synaptophysin (F), PSD-95 (G), and colocalized (H) puncta, determined from four experiments using independent cultures. *p < 0.05, Student's t test. Graphs show means ± SEM. See also Figure S4 .
Cell Metabolism TNF-a, PKR, Insulin Signaling, and Memory the beneficial actions of GLP-1R agonists in AD transgenic mice involve decreased AbO levels and attenuation of brain eIF2a-P and ER stress. Finally, systemic treatment with liraglutide reduced eIF2a-P induced by AbOs in the entorhinal cortex and hippocampus of two cynomolgus monkeys ( Figures 6F-6H ).
DISCUSSION
An intriguing molecular connection has been established between type 2 diabetes and AD, following the discovery that impaired insulin signaling, a hallmark of diabetes, is present in AD brains (Bomfim et al., 2012; Talbot et al., 2012) . Clinical and epidemiological studies have further linked AD and diabetes, with each disease increasing the risk of developing the other (Ott et al., 1996; Janson et al., 2004) . AbOs, synaptotoxins that accumulate in AD brains (Gong et al., 2003) have provided initial evidence that mechanisms similar to those underlying peripheral insulin resistance in metabolic diseases lead to impaired brain insulin signaling in AD (Bomfim et al., 2012; Talbot et al., 2012; De Felice, 2013) . AbOs exert multiple neurotoxic actions, including disruption of neuronal calcium homeostasis (De Felice et al., 2007; Mattson, 2010) , abnormal ER calcium release (Paula-Lima et al., 2011) , and activation of JNK (De Felice et al., 2009; De Felice, 2013) , conditions known to favor the development of ER stress in peripheral tissues (Hotamisligil, 2010) . ER stress plays a key role in metabolic disorders, including type 2 diabetes and obesity, and is linked to peripheral insulin resistance and inflammation (Ozcan et al., 2004) . Elevated ER stress markers, including eIF2a-P, have been reported in AD brains (Hoozemans et al., 2009; Yoon et al., 2012) . Using different experimental models, including monkeys that received i.c.v. injections of AbOs, we demonstrate here that eIF2a-P and other ER stress responses are induced by AbOs in neurons. Our findings are in accord with studies that reported elevated levels of ER stress markers in other cellular and animal models of AD (Yoon et al., 2012) and indicate that pathological findings in those studies can be attributed to the toxic impact of AbOs.
We have identified PKR as an eIF2a kinase activated by AbOs in neurons and shown that AbOs act via the TNF-a pathway to activate PKR. Active PKR, present in AD brains (Bullido et al., 2008) , is an important mediator of inflammation and IRS-1 dysfunction in metabolic diseases (Nakamura et al., 2010; Gregor and Hotamisligil, 2011) . Of direct relevance to the current study, PKR was recently shown to be involved in neuronal IRS-1 inhibition triggered by AbOs (Bomfim et al., 2012) and to negatively regulate memory in mice (Zhu et al., 2011) . Current findings indicate that PKR activation does not depend on direct binding of oligomers to individual neurons, as elevated phospho-PKR and eIF2a-P levels were detected in neurons regardless of whether or not they had oligomers bound to their dendrites. Therefore, AbOs do not seem to act directly on neurons to phosphorylate PKR. Rather, it is likely that a crosstalk between neurons and microglia leads to elevated levels of TNF-a, causing Figure 6 . Antidiabetic Agents Block AbO-Induced eIF2a-P In Vitro and In Vivo (A) PKR-pThr451 immunolabeling in cultured hippocampal neurons exposed for 3 hr to vehicle or 500 nM AbOs in the absence or presence of 1 mM insulin (scale bar = 10 mm). (B) PKR-pThr451 immunofluorescence levels, determined from four experiments using independent cultures. (C) eIF2a-P immunolabeling in hippocampal neurons exposed for 3 hr to 500 nM AbOs, 1 mM insulin + 500 nM AbOs, or 300 nM exendin-4 + 500 nM AbOs (scale bar = 10 mm). (D) eIF2a-P immunofluorescence levels (n = 3 experiments using independent cultures; 30 images analyzed per experimental condition per experiment). **p < 0.01, ANOVA followed by Bonferroni post hoc test. (E) Immunoblot analysis for eIF2a-P in hippocampal homogenates from 13-to 16-month-old APP/PS1 (n = 7) or exendin-4-treated APP/PS1 (n = 5) mice. Graphs show means ± SEM. (F) eIF2a-P immunolabeling in the hippocampi (representative images from CA3) and entorhinal cortices of sham, AbO-injected, or liraglutide-treated and AbO-injected monkeys (scale bars = 200 mm). (G and H) eIF2a-P immunolabeling densities in the hippocampi (G) and entorhinal cortices (H) of sham (white bar), AbO-injected (black bar), or liraglutide-treated AbO-injected monkeys (gray bars). Graphs show means ± SEM obtained for different animals in each experimental group (n = 3, 4, or 2 for sham, AbO-injected, or liraglutide-treated AbO-injected monkeys, respectively). Asterisk indicates a statistically significant (p < 0.05; Student's t test) difference between sham and AbO-injected animals. See also Figure S6 .
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and Memory activation of neuronal TNF-a/PKR/eIF2a signaling. TNF-a has been suggested recently to play a role in brain dysfunction in different diseases, including AD, trauma, and Parkinson's disease (Clark et al., 2012) . Elevated TNF-a levels are further thought to cause cognitive deficits (He et al., 2007) . Our results demonstrate that, in Alzheimer's disease, elevated TNF-a is a consequence of the brain accumulation and impact of AbOs.
AD is a devastating disease affecting memory. AbOs are recognized as potent synaptotoxins that inhibit synaptic plasticity (Ferreira and Klein, 2011) . We found here that oligomerinduced aberrant TNF-a/PKR/eIF2a signaling and induction of ER stress are linked to synapse loss and memory impairment. It is notable that, in both PKR À/À and TNFR1 À/À mice, oligomers failed to trigger eIF2a-P and cognitive impairment. Inhibition of PKR was found to attenuate the loss of PSD-95 and synaptophysin induced by AbOs, implicating synapse deterioration in the deleterious impact of PKR on memory. PKR and eIF2a have both been shown to be critical for memory regulation (CostaMattioli et al., 2007; Zhu et al., 2011) . More recently, eIF2a-P was found to mediate prion-related neurodegeneration in the hippocampus (Moreno et al., 2012) . We report that upregulation of eIF2a-P triggers synapse loss, suggesting that synergistic neurotoxic events that culminate in eIF2a-P may respond, at least in part, for synapse damage in AD. Our results thus establish that AbO-induced TNFa, PKR, and eIF2a-P dysregulation is directly linked to synapse failure and cognitive impairment, revealing a mechanism by which AbOs disrupt memory in AD. The parallel we now describe between AD and diabetes sheds light on how insulin signaling is impaired in AD. In peripheral tissues, inflammatory and metabolic stress signaling cascades trigger disruption of insulin signaling (Ozcan et al., 2004 (Ozcan et al., , 2006 Hotamisligil, 2010; Nakamura et al., 2010; Gregor and Hotamisligil, 2011) . Our findings show that ER stress is linked to neuronal IRS-1 inhibition and may act synergistically with proinflammatory signals to disrupt brain insulin signaling in AD.
It is important to note that our conclusion that TNF-a signaling is linked to both defective brain insulin signaling and memory impairment caused by AbOs does not necessarily imply that memory impairment is a direct consequence of disruption of insulin signaling. In fact, the role of insulin signaling in memory formation, and how defective signaling might result in neurodegenerative disorders, is still under investigation. While insulin has been shown to positively modulate hippocampal synaptic plasticity (van der Heide et al., 2005) , an early study showed that spatial memory was preserved in neural-specific insulin receptor b subunit knockout (NIRKO) mice (Schubert et al., 2004) . A recent study, however, reported that IRb haploinsufficiency causes reduced brain insulin signaling and defects in late-phase long-term potentiation (LTP) and long-term recognition memory storage, thereby implicating insulin receptor (IR)-dependent mechanisms in memory formation (Nisticò et al., 2012) . Significantly, intranasal insulin administration has been found to enhance memory in healthy volunteers (Benedict et al., 2004) , in memory-impaired older subjects (Reger et al., 2006) , and in early AD patients (Craft et al., 2012) , with beneficial effects reported for both acute and long-term insulin treatment.
In sporadic AD (which corresponds to >90% of AD cases), the exact mechanism that leads to accumulation of Ab oligomers and amyloid in the brain remains to be fully elucidated. Interestingly, eIF2a-P promotes BACE1 expression, Ab production, and deposition (O'Connor et al., 2008) . Thus, AbO-induced TNF-a, PKR, and eIF2a-P may constitute a hub in a feedforward deleterious cycle involving increased AbO generation and perpetuation and amplification of neuronal dysfunction.
In line with our current findings demonstrating that eIF2a-P is sufficient to cause synapse loss and memory impairment in mice, a very recent study showed that the eIF2a kinase PERK mediates Ab-induced LTP impairment (Ma et al., 2013) . Importantly, Ma and colleagues further reported that genetically suppressing the eIF2a kinases PERK or GCN2 prevented spatial memory impairment in AD mice (Ma et al., 2013) . Although the complete set of mechanisms remains to be elucidated, it is conceivable that TNF-a represents an initial trigger that orchestrates activation of multiple stress response pathways (of which the PKR/eIF2a pathway here investigated appears central) that culminate with synapse dysfunction and memory loss in AD.
In recent years, there has been a strong effort to develop new therapeutic strategies for diabetes and insulin resistance disorders. GLP-1 receptor stimulation has insulinotropic action and restores glucose homeostasis in peripheral tissue (Yusta et al., 2006) , and several GLP-1 analogs are currently used for diabetes treatment. We demonstrate here that both insulin and GLP-1R agonists prevent abnormal neuronal phospho-PKR and eIF2a-P. The observation that insulin protects neurons from AbO-induced PKR activation suggests that blockade of eIF2a-P by insulin is mediated by suppression of PKR. Recent studies have shown beneficial effects of exendin-4 and liraglutide against neurodegeneration and cognitive impairment in AD models McClean et al., 2011; Bomfim et al., 2012) , but the signaling mechanisms involved in neuroprotection are only partially known. The present study suggests a mechanism involving suppression of the PKR/eIF2a-P pathway. Importantly, we provide evidence that a GLP-1R agonist exerts neuroprotective actions in the primate brain, as systemic liraglutide treatment reduced oligomer-induced brain eIF2a-P in monkeys.
In conclusion, our findings establish that activation of TNF-a signaling mediates AbO-induced brain IRS-1 inhibition and PKR-dependent eIF2a-P, synapse loss, and memory impairment (Figure 7) , revealing mechanisms that lead to synapse loss and memory impairment. Identifying a pathogenic mechanism that is shared between AD and diabetes and contributes to memory loss in AD may open avenues for rapid implementation of clinically approved antidiabetic drugs as therapeutics in AD.
EXPERIMENTAL PROCEDURES Ab Oligomers
Oligomers were prepared weekly from synthetic Ab 1-42 and routinely characterized by size-exclusion chromatography and, occasionally, by western immunoblots and transmission electron microscopy, as previously described (De Felice et al., 2007 Sebollela et al., 2012) . Oligomers were kept at 4 C and used within 48 hr of preparation.
Mature Hippocampal Cultures
Primary rat hippocampal neuronal cultures, prepared and developed in Neurobasal Medium supplemented with B27 (Invitrogen) and antibiotics according to established procedures (De Felice et al., 2007) , were used after
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TNF-a, PKR, Insulin Signaling, and Memory 18-21 days in vitro. All procedures were approved by the Institutional Animal Care and Use Committee of the Federal University of Rio de Janeiro (protocol #IBqM 022). Cultures were exposed at 37 C for 3 hr to 500 nM Ab oligomers or an equivalent volume of vehicle (2% DMSO in phosphate-buffered saline [PBS] ). When present, PKR inhibitor (1 mM), insulin (1 mM), exendin-4 (300 nM), SP600125 (10 mM), or infliximab (1 mg/mL) were added to cultures 30 min before Ab oligomers. For ER stress induction, thapsigargin (1 mM) was added to neuronal cultures for 3 hr, and in some experiments 4-phenylbutyrate (4-PBA) (1 mM) was also present. For eIF2a-P induction, salubrinal (10 mM) was added to neuronal cultures for 3 hr.
Experimental Subjects
Male Swiss mice were obtained from our animal facility (Federal University of Rio de Janeiro) and were 2.5-3 months old at the beginning of experiments. PKR À/À male mice on a 129/SvEv background (Yang et al., 1995) were obtained from Federal University of Minas Gerais Animal Centre. 129/SvEv wild-type mice were used as controls for experiments with PKR À/À mice.
) female mice on a C57BL/6 background (Pfeffer et al., 1993) were obtained from the University of Campinas Breeding Centre and were 3 months old at the beginning of experiments. C57BL/6 wild-type mice were used as controls for experiments with TNFR1 À/À mice. APPSwe/ PS1DE9 mice on a C57BL/6 background (Jankowsky et al., 2001) were obtained from The Jackson Laboratory. Wild-type littermates were used as controls. Animals were genotyped prior to the studies using specific primers (see Supplemental Experimental Procedures). All procedures involving transgenic mice were approved by the Institutional Animal Care and Use Committee of the Federal University of Rio de Janeiro (protocol #IBqM 055). Animals were housed in groups of five in each cage with free access to food and water, with controlled room temperature and humidity, and under a 12 hr light/12 hr dark cycle. All procedures used in the present study followed the ''Principles of Laboratory Animal Care'' from the US National Institutes of Health.
Intracerebroventricular Injections in Mice
For i.c.v. injection of AbOs, animals were anesthetized for 7 min with 2.5% isoflurane (Cristá lia) using a vaporizer system and gently restrained only during the injection procedure itself, as described Ledo et al., 2013) . A 2.5 mm long needle was unilaterally inserted 1 mm to the right of the midline point equidistant from each eye and 1 mm posterior to a line drawn through the anterior base of the eye . AbOs (10 pmol), 1 mg of thapsigargin, or vehicle was injected in a final volume of 3 ml, and the needle was kept in place for 30 s to avoid backflow. Before euthanasia, blue staining was injected using the same hole used previously, which allowed us to determine the accurate placement of the injection. Behavioral results from mice that showed signs of misplaced injections or any sign of hemorrhage were excluded from the final statistical analysis (this happened in 5% of cases, on average).
In Vivo Drug Treatments in Mice
Exendin-4 and liraglutide are two long-lasting GLP-1 receptor agonists. APPSwe/PS1DE9 mice (13-14 months old) received daily intraperitoneal injections of exendin-4 (25 nmol/kg, dissolved in saline) or vehicle (saline) for 3 weeks. Another group of transgenic animals received daily intraperitoneal injections of liraglutide (25 nmol/kg, dissolved in saline) or vehicle (saline) for 6 weeks. Male Swiss mice (3 months old) received daily intraperitoneal injections of infliximab (20 mg/day) for 7 days starting immediately after i.c.v. injection of AbOs. In experiments with 4-phenylbutyrate (4-PBA), one intraperitoneal injection (200 mg/kg) was given immediately after i.c.v injection of either Ab oligomers or thapsigargin in male Swiss mice. 4-PBA solutions were prepared as described. Salubrinal (1 mg/kg) or vehicle was administered intraperitoneally in 3-month-old male Swiss mice for 7 days before cognitive analysis (Moreno et al., 2012) . All procedures were approved by the Institutional Animal Care and Use Committee of the Federal University of Rio de Janeiro (protocol #IBqM 041).
Intracerebroventricular Injection of Ab Oligomers in Monkeys and Treatment with Liraglutide
Adult cynomolgus monkeys (Macaca fascicularis) (n = 9) were used (body weights 4.7-7.0 kg). All procedures were approved by the Queen's University Animal Care Committee and were in full compliance with the Canada Council on Animal Care (Animal Care Protocol Original Munoz-2011-039-Or). Animals were under the close supervision of an animal technician and the institute veterinarian. AbOs were infused chronically through an intracerebroventricular cannula. A total of 4 animals received 100 mg Ab oligomers i.c.v. every 3 days for 24 days, while 3 animals served as sham-operated controls. Control animals had the cannula implanted into the lateral ventricle in the same manner as the experimental animals but did not receive oligomer injections. Two additional animals received daily subcutaneous injections of liraglutide (25 nmol/kg) beginning 1 week prior to Ab oligomer infusion and continuing until the end of AbO injections. Oligomers were freshly prepared and characterized by size-exclusion chromatography before each injection. Upon completion of the experimental protocol, animals were sedated with ketamine (10 mg/kg, intramuscular) plus buprenorphine (0.01 mg/kg) for analgesia, followed by intravenous sodium pentobarbital (25 mg/kg). Next, animals were perfused with PBS and then, sequentially, by 4% paraformaldehyde in PBS, 4% paraformaldehyde in PBS containing 2.5% glycerol, PBS + 5% glycerol, and PBS + 10% glycerol. Serial brain sections (40 mm thick) were obtained, and neuropathological analyses were performed. Ab oligomers lead to increased brain levels of TNF-a, leading to TNFR1-mediated activation of PKR and other stress kinases. Activated PKR phosphorylates neuronal IRS-1 (see also Bomfim et al., 2012) and eIF2a. Increased eIF2a-P levels trigger synapse loss and memory impairment.
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Statistical Analysis
All analyses were performed with GraphPad Prism, and data sets were assessed for normality parameters prior to significance determination. Values are expressed as means ± SEM, unless otherwise stated. Statistical confidence levels are indicated in each figure (*p < 0.05; **p < 0.01). 
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